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Abstract
Background: Morphine is worldwide the analgesic of first choice after cardiac surgery in children. Morphine has
unwanted hemodynamic and respiratory side effects. Therefore, post–cardiac surgery patients may potentially
benefit from a non-opioid drug for pain relief. A previous study has shown that intravenous (IV) paracetamol is
effective and opioid-sparing in children after major non-cardiac surgery. The aim of the study is to test the hypothesis
that intermittent IV paracetamol administration in children after cardiac surgery will result in a reduction of at least 30%
of the cumulative morphine requirement.
Methods: This is a prospective, multi-center, randomized controlled trial at four level-3 pediatric intensive care units
(ICUs) in the Netherlands and Belgium. Children who are 0–36 months old will be randomly assigned to
receive either intermittent IV paracetamol or continuous IV morphine up to 48 h post-operatively. Morphine
will be available as rescue medication for both groups. Validated pain and sedation assessment tools will be
used to monitor patients. The sample size (n = 208, 104 per arm) was calculated in order to detect a 30%
reduction in morphine dose; two-sided significance level was 5% and power was 95%.
Discussion: This study will focus on the reduction, or replacement, of morphine by IV paracetamol in
children (0–36 months old) after cardiac surgery. The results of this study will form the basis of a new pain
management algorithm and will be implemented at the participating ICUs, resulting in an evidence-based
guideline on post-operative pain after cardiac surgery in infants who are 0–36 months old.
Trial registration: Dutch Trial Registry (www.trialregister.nl): NTR5448 on September 1, 2015. Institutional review
board approval (MEC2015–646), current protocol version: July 3, 2017
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Background
Congenital heart disease accounts for almost one
third of all congenital anomalies, and the reported
total prevalence in Europe is 8.0 in 1000 births [1, 2].
Surgical intervention is necessary in 55% within the
first year of life and in 67% during the first three
years of life [3].
The importance of adequate post-surgical pain relief
in neonates and infants became apparent after find-
ings that untreated pain results in increased stress
hormone levels and prolonged behavioral conse-
quences [4]. These findings have resulted in an
increased use of morphine as the worldwide standard
for pain relief after major surgery in neonates and
children [5–9]. However, morphine can cause
unwanted hemodynamic and respiratory reactions and
therefore patients could potentially benefit from a
non-opioid analgesic.
In a recent randomized controlled trial, intravenous
(IV) paracetamol was compared with morphine as a
primary analgesic drug in non-cardiac post-operative
children up to 1 year. IV paracetamol was equally
effective in pain relief, and no difference in rescue
analgesics was shown between groups [10]. The IV
paracetamol group had a lower cumulative morphine
dose the first 48 h after surgery and less adverse drug
reactions. Whether these results also apply to neo-
nates and children after cardiac surgery is unclear.
Pharmacokinetic (PK) parameters are assumed to be
different in patients during and after cardiac surgery
compared with non-cardiac surgery, and changes in
pharmacodynamics (PD) and pharmacogenetics con-
cerning pain perception need to be taken into
account.
Cardiothoracic surgery
Based on the general anesthesia guidelines, opioids are
considered standard of care in children to prevent and
treat post-operative pain after cardiac surgery even
though clear PK data are lacking [11]. There are reasons
to assume that children after cardiac surgery have differ-
ent PK or PD (or both) compared with adults or chil-
dren after non-cardiac surgery. Valkenburg et al.
describe a lower clearance of morphine and a higher vol-
ume of distribution in 38 children after cardiac surgery
compared with non-cardiac surgery, possibly necessitat-
ing a different dosing regimen [12].
The use of cardiopulmonary bypass (CPB) is the
main reason to expect PK changes. CPB has a pro-
found effect on the PK parameters because of
hemodynamic changes, hemodilution, hypothermia,
and systemic inflammatory reactions (systemic inflam-
matory response syndrome, or SIRS). These effects
change constantly throughout CPB and some
continue to exert an influence after the patient has
been successfully weaned from CPB [13].
Hemodynamic changes affect organ perfusion and
ultimately organ function. Hemodynamics may also be
altered by the need for inotropic support during and
after surgery. Children with a normal cardiovascular
system undergoing surgery seem to clear morphine
more efficiently than infants undergoing cardiovascu-
lar surgery [14]. On initiation of CPB, prime fluid
causes dilution of the patient’s blood. This causes a
shift in the bound and unbound fraction of the drug
and a redistribution from peripheral to central com-
partments. Decreased renal and hepatic perfusion due
to hypothermia, hypotension, decreased flow rate, and
hemodilution may result in decreased elimination of
drugs [13].
Surgical correction of more complex congenital car-
diac defects has an additional influence on systemic
circulation influencing the PK of drugs itself because
of longer CPB run times with higher risk for severe
SIRS and hemodynamic instability [13, 15, 16]. How-
ever, there is currently no literature suggesting a dif-
ference in sedative or analgesic requirements based
on type of congenital defect or surgical procedure.
Morphine
The elimination of morphine is mainly through glucuro-
nidation by urine diphosphate glucuronosyltransferase
(UGT) 2B7. Morphine clearance directly reflects the
formation of its two major metabolites that are pharma-
cologically active: morphine-3-glucuronide (M3G) and
morphine-6-glucuronide (M6G). Both metabolites are
cleared through renal elimination, and a reduced
renal function can lead to accumulation. Evidence
suggests that clearance of morphine is significantly
slower in children who need inotropic support after
cardiac surgery [17].
The unwanted hemodynamic and respiratory effects
of morphine are a particular problem in these
hemodynamically unstable children and may lead to
delayed recovery and prolonged pediatric intensive
care unit (PICU) stay [18, 19]. Another adverse effect
of morphine is intestinal obstruction, which occurs
mainly in younger children, whereas nausea, vomiting,
and itching occur mainly in older children [7].
Paracetamol
The analgesic effect of paracetamol is not yet fully
understood but is likely due to interaction with the
serotonergic system. Glucuronidation is the major
pathway of paracetamol metabolism (50–60%) and
there is a contribution of sulfation (25–44%) and oxi-
dation (2–10%). Glucuronidation and sulfation result
in inactive and non-toxic end products. The hepatic
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oxidation pathway forms NAPQI (N-acetyl-p-benzo--
quinone imine) [20]. NAPQI is toxic and, in the case
of overdose, causes mitochondrial dysfunction and
centrilobular necrosis in the liver [21]. Several studies
show that, when it is used in therapeutic doses in
children without liver dysfunction, the safety profile is
excellent [20].
Enteral or rectal dosing is sufficient for mild to
moderate pain. However, after major surgery, rectal
administration of paracetamol was shown to be in-
sufficient to reach a therapeutic level for pain relief
and does not reduce the morphine consumption
[22–24]. Potentially, IV paracetamol performs better
in the case of severe or acute pain. IV paracetamol
rapidly penetrates an intact blood-brain barrier in
children, which contributes to the fast onset of the
analgesic effect [25, 26, 27].
Pharmacogenetics
A large number of candidate gene studies have illus-
trated associations between genetic variants with
opioid response [28, 29] and paracetamol efficacy
[30]. The genetic impact can arise from polymor-
phisms in genes that alter drug levels (PK) such as
metabolizing enzymes and transporters. PK genes
relevant for morphine are UGT2B7, ABCC3, and
OCT1 [31–33].
Hypothesis
Our hypothesis is that intermittent IV paracetamol is
effective as the primary analgesic drug in post-cardiac
surgery patients up to 3 years of age and that the use
of IV paracetamol will reduce overall morphine
requirements.
This hypothesis is currently being tested at three
level-4 PICUs in the Netherlands and Belgium (Erasmus
MC-Sophia Rotterdam, Wilhelmina Children’s Hospital
University Medical Center (UMC) Utrecht, Beatrix
Children’s Hospital UMC Groningen, University
Hospital (UZ) Leuven).
Methods
Trial design
This study is a multi-center, prospective, randomized,
double-blind study with a non-inferiority design.
Study setting
The study will be conducted at four level-3 PICUs in
the Netherlands and Belgium (Erasmus MC-Sophia
Rotterdam, Wilhelmina Children’s Hospital UMC
Utrecht, Beatrix Children’s Hospital UMC Groningen
and UZ Leuven).
Interventions
All patients will receive a loading dose of morphine
100 μg/kg at the end of surgery. After the loading
dose, patients are randomly assigned to receive ei-
ther a morphine continuous infusion or intermittent
IV paracetamol. A double dummy (intermittent or
continuous infusion of NaCl 0.9%) will be used in
each group to ensure blinding. Patients in the inter-
vention group receive intermittent IV paracetamol.
Justification of dosing
Howard et al. prospectively evaluated effectiveness,
morphine requirements, and safety of IV morphine in
over 10,000 pediatric patients, including almost 1000
patients after cardiac surgery in a tertiary care hos-
pital [34]. Patients after cardiac surgery had the high-
est morphine requirements—an average dose of 23
μg/kg per h (5–50 μg/kg per h)—but PK data were
not collected and it is unclear whether morphine dos-
ing was based on validated pain scores. Lynn et al.
described morphine serum levels of 15–20 ng/mL in
infants after cardiac surgery with continuous mor-
phine infusions of 10–20 μg/kg per h without de-
scribing analgesic efficacy [9]. These morphine serum
levels are typically associated with adequate pain relief
[17]. In 2009, Knibbe et al. proposed a novel mor-
phine dosing regimen for neonates and children on
the basis of PK studies, resulting in a significant dose
reduction of morphine in neonates of less than 10 days
post-natal age [35]. This model was further validated
with new datasets [36] and ultimately resulted in a
prospective randomized controlled trial in which the
proposed dosing regimen for morphine dosing was
evaluated [37]. This morphine dosing regimen was
used in the previous trial comparing continuous IV
morphine with intermittent IV paracetamol after
major non-cardiac surgery.
Several studies have determined paracetamol metab-
olism in children [38, 20]. PK of IV paracetamol in
children until the age of 16 years have been de-
scribed; however, no children undergoing cardiac sur-
gery were included in this study [39, 40].
IV paracetamol will be dosed in accordance with
the Dutch pediatric formulary with a loading dose of
20 mg/kg and maintenance dose of 10 mg/kg
(<1 month of age) or 15 mg/kg (>1 month) [41].
Worldwide, IV paracetamol is given in three or
four dosages daily and not as continuous infusion.
Even though continuous administration of IV para-
cetamol is possible, limited evidence in healthy
adults shows that the analgesic effect of IV paraceta-
mol is better with intermittent administration [42].
Therefore, different delivery schedules for morphine
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(continuous) and paracetamol (intermittent) are
selected.
Control group
Patients in the control group will receive a continu-
ous morphine infusion after the loading dose of mor-
phine 100 μg/kg. Using our PK data on morphine in
non-cardiac and cardiac pediatric patients [35, 37,
40], we developed a new morphine dosing regimen
for neonates and children who are 0 to 36 months
old. The dosing algorithm is presented as Table 1, in
the Appendix.
Use of co-intervention
Standard post-operative care is given to all patients
with analgesic rescue medication. Short-acting analge-
sics and sedatives are available during interventions,
such as chest drain removal. All co-medications used
during the first 48 h after surgery are registered in
the database.
Rescue analgesic medication
Rescue morphine will be administered with a maximum
of three times per hour whenever the Numeric Rating
Scale (NRS) score is at least 4. Standard additional dose
of morphine is 10 μg/kg for patients who are less than
10 days post-natal age and 15 μg/kg for patients who are
at least 10 days.
Ten minutes after each extra dose of morphine,
pain is re-assessed. If there is no improvement in the
scores (i.e., NRS score ≥4) after three additional
(rescue) doses, a morphine loading dose of 100 μg/kg
is given and a continuous morphine infusion is
started at 10 μg/kg per h in a separate pump (to en-
sure blinding). Whenever pain is not responding to
the extra morphine boluses and the additional con-
tinuous morphine infusion in a maximum dose of 30
μg/kg per h, fentanyl is started at 1–2 μg/kg loading
dose and 1–3 μg/kg per h continuous infusion. At
the start of fentanyl, morphine will be discontinued.
In case of discomfort, midazolam is started. Discom-
fort is determined as COMFORT-Behavior scale
(COMFORT-B) score of more than 22 or
COMFORT-B score between 11 and 22 but with the
Nurse Interpretation of Sedation Score (NISS)
suggesting undersedation. Standardized sedation will
be part of the treatment protocol. Sedation protocols
regarding the primary sedatives are already compar-
able between the participating ICUs. This treatment
algorithm is similar to the one used in the recent
study comparing morphine and paracetamol in
non-cardiac patients [10].
In both groups, continuous morphine infusion (if started)
will be decreased in the second 24 h depending on the NRS
and COMFORT-B scores.
If discharge from the ICU occurs within 48 h after
surgery, the study medication will be continued on
the ward. The arterial catheter will be removed at
discharge from the ICU. PK sampling on the ward
will only be carried out simultaneously with routine
blood examination. At 48 h after surgery, the study
medication will be changed to open-label paraceta-
mol and rescue morphine if needed.
PD outcome measurements
PD outcomes will be measured by using validated instru-
ments. Both pain and under- and over-sedation need to be
assessed. Signs of pain and distress may overlap, making ac-
curate assessment difficult. Therefore, the use of concomi-
tant sedative drugs will be standardized in the participating
ICUs. The COMFORT-B is mainly a distress assessment
and, to a lesser extent, a pain instrument that asks observers
to consider the intensity of six behavioral manifestations:
alertness, calmness, respiratory response (for mechanically
ventilated children) or crying (for spontaneously breathing
children), body movements, facial tension, and muscle tone.
For each of these items, five descriptions, rated from 1 to 5,
reflecting increasing intensity of the behavior in question,
are provided. Summating the ratings of the six behavioral
manifestations leads to a total score ranging from 6 to 30.
The COMFORT-B has been extensively validated in
post-operative infants with or without Down syndrome and
in infants after major cardiac surgery [43–46].
The NRS for pain is a scale from 0 (no pain) to 10
(worst possible pain) and is used in conjunction with
the COMFORT-B to represent the rater’s expert
opinion [47]. The NRS focusses on pain, whereas the
COMFORT-B assesses mainly discomfort. Any add-
itional rescue morphine is given when the NRS score
is 4 or higher. This dose escalation schedule is con-
sistent with additional analgesic treatment in the
normal clinical setting.
Using the NRS, parents will be able to participate
in rating the pain in their children. This will be used
alongside the nurses’ NRS and COMFORT-B. Parents
will receive a very short instruction explaining the
different factors that should be taken into account
when assigning the NRS.
Parents’ participation will be on a voluntary basis.
If parents indicate that active participation is not
wanted anymore, they will be able to stop at any
time. Variation in nurse and parent evaluation of
pain or discomfort will be analyzed as a secondary
endpoint.
The NISS has been validated for this age group
and represents the caregiving nurse’s expert opinion
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and is scored as 1 = undersedation, 2 = adequate sed-
ation, or 3 = oversedation [47].
Follow-up will consist of the “Parents’ Postopera-
tive Pain Measurement–Short Form” (PPPM-SF) to
complete after discharge from the hospital. This tool
includes 10 items asking parents about signs of pain
and distress at home in children after surgical inter-
vention [48]. Parents will be called 2 d after dis-
charge from the hospital to inform after the child’s
health and to take the questionnaire.
Patients after major cardiac surgery are also at risk
for opioid withdrawal syndrome and pediatric delir-
ium. Therefore, these two conditions were assessed as
well [33, 49].
The Sophia Observation withdrawal Symptoms
(SOS) scale has been validated to detect withdrawal
syndrome in critically ill children. It contains 15 items
that are scored as either not present (0) or present
(1). A score of 4 or higher suggests withdrawal syn-
drome [50, 51].
Pediatric delirium in our study will be assessed by
using the SOS-PD scale and Cornell Assessment of
Pediatric Delirium (CAPD) [52]. The SOS-PD scale con-
sists of 17 items and the maximum total sum score is 17
points. A total score of at least 4 is used as a cutoff for
delirium or when the item “hallucination” is scored posi-
tive. The CAPD consist of eight items, scoring the inter-
action of the nurse with the patient. The maximum total
sum score is 32 points, and the cutoff for delirium is 9
points or greater. In accordance with standard local
protocol, a pediatric psychiatrist will be consulted in
case of delirium. Treatment of delirium will be carried
out in accordance with local protocol [53].
Severity of illness will be estimated with the vali-
dated Pediatric Risk of Mortality III score [54]
together with the more specific Risk-Adjusted Classi-
fication for Congenital Heart Surgery (RACHS-1)
score [55]. All Dutch hospitals use the Aristotle
score to classify the congenital cardiac surgery
patients. This Aristotle score will also be used to es-
timate the severity of surgical procedure and to
compare the two groups with respect to the surgical
intervention [56, 57]. The Pediatric Logistic Organ
Dysfunction 2 (PELOD-2) score will be used to
assess the severity of cases of multiple organ dys-
function syndrome in the PICU on day 0 (day of
surgery), day 1, and day 2 [58].
PK analysis and blood sampling
Blood samples will be drawn for PKPD analysis by
using an indwelling arterial catheter. Blood samples
will be taken after the morphine bolus dose, directly
after the start of trial medication, 30–60 min after
the start of trial medication, 3–4 h after the start of
trial medication, and at three standard moments
during the day. The timing of the standard sampling
moments is dependent on local clinical practice. Be-
cause of small timing differences, this will create a
diverse sampling scheme, which is very applicable
for PKPD analysis. Also, samples will be taken before
and after changes in the dose of analgesic medica-
tion. For ethical reasons, not more than 5% of the
total blood volume will be drawn from the patient.
Thus, PK samples will be obtained by sparse sam-
pling with a minimal burden to the individual
patients. Using population PK analysis, the data
points from the individual subjects will be combined
to form solid PK data on morphine and paracetamol
and their metabolites since these metabolites are
biologically active. The population PK analysis will
be carried out by using non-linear mixed-effect mod-
eling (NONMEM).
DNA analysis will be performed to evaluate interin-
dividual variability drug responses. Genetic variability
of morphine and paracetamol will be the main focus.
Eligibility criteria and parental consent
Patients eligible to participate in the study will be in-
fants and children (0–36 months) who are admitted
to the ICU after cardiac surgery with the use of the
CPB. Information regarding the trial will be given to
parents, or authorized surrogates, of potential trial
participants at the out-patient clinic or on the ward.
Information will be given by a researcher, either the
doctor or research nurse. Written informed consent is
obtained from all trial participants before surgery.
Inclusion criteria
 Informed consent
 Neonates/infants who are 0–36 months old
 Cardiac surgery with the use of CPB.
Exclusion criteria
 No informed consent
 Known allergy to or intolerance of paracetamol or
morphine
 Administration of opioids in the 24 h prior to
surgery
 Hepatic dysfunction defined as three times the
reference value of alanine aminotransferase/aspartate
aminotransferase (ALAT/ASAT)
 Renal insufficiency defined as Pediatric RIFLE (Risk,
Injury, Failure, Loss, End Stage Renal Disease)
category; injury is defined as estimated creatinine
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clearance reduced by 50% and urine output of less
than 0.5 mL/kg per h for 16 h.
If patients develop renal or hepatic insufficiency
after randomization, they will be withdrawn from the
trial.
Primary objectives
The primary objective is to test the hypothesis that anal-
gesia with intermittent IV paracetamol will lead to a
morphine-sparing effect of at least 30% as compared
with model-based continuous IV morphine infusion dur-
ing the first 48 h after cardiac surgery in infants who are
0–36 months old.
The primary outcome measure is weight-adjusted
cumulative morphine consumption (in micrograms per
kilogram) in the first 48 h post-operatively.
The reduction of morphine has been chosen as the
primary outcome since this is directly related with
the decrease of morphine-related adverse drug reac-
tions. The previous trial comparing IV paracetamol
with morphine clearly showed a reduction of
morphine-related adverse drug reactions in the IV
paracetamol group. Among these drug reactions are
gastrointestinal symptoms, which are also described
as two out of six endpoints in the recent Standar-
dised Endpoints in Perioperative Medicine (StEP)
recommendations for patient comfort [59].
Secondary objectives
1. Incidence of adverse drug reactions
a. Hemodynamic: hypotension or bradycardia,
with the need for intervention by means of
medication or a fluid bolus
b. Decreased gastrointestinal motility or intestinal
obstruction not directly related to the
underlying diagnosis and not previously existing,
with the need for intervention
c. Vomiting
d. Number of re-intubations
e. Pediatric delirium as measured by the SOS-PD
scale or CAPD score
2. Non-inferiority analysis of comparing patients with
one or more NRS scores of at least 4 between
groups
3. DNA analysis will be performed to evaluate the
effect of gene polymorphisms on the PK of
analgesic medication
4. Concomitant use of sedatives
5. The number of hours on ventilation
6. The length of PICU stay
7. Role of alarmins in the systemic inflammatory
response (only at Wilhelmina Children’s Hospital,
UMCUtrecht).
8. To develop a population PKPD-based post-operative pain
management algorithm based on the results of this trial.
Sample size calculation
We estimate that the required morphine dose in the
paracetamol group can be reduced by at least 30%
compared with the morphine group in the first 48 h
after surgery. This is in line with the outcome of a
previous study we conducted in a 0- to 1-year-old
patient group after major non-cardiac surgery with
similar study medication [10].
The power analysis is based on a comparison of
the primary outcome between groups using a
Mann-Whitney test. A simulation study was carried
out for this power analysis using data on the cumu-
lative morphine dose from a previous study with
comparable morphine dosing [10]. Based on this
dataset, the median cumulative morphine dose was
357 μg/kg (interquartile range of 220–605) in the
control group, and we assumed that this morphine
dose would be reduced by 30% in the intervention
group. The simulation study showed that, with a
two-sided significance level of 5%, 86 patients per
group would be required to obtain a power of 95%.
To account for the effects of stratification by center
and missing data, we will include 104 patients per
study arm (208 in total). We expect this sample size
to be sufficient to assess secondary outcomes.
As described above, the primary endpoint of the
study is the total amount of morphine administered
in the first 48 h after surgery. Any additional mor-
phine given will be based on NRS scores of 4 or
higher. Therefore, in a secondary, non-inferiority
analysis, we will also compare the percentage of
patients with one or more NRS scores of 4 or higher
between the two groups, using a non-inferiority mar-
gin of 20%, based on the previous trial and clinical
experience. NRS scores are assessed often per patient
and should give a clear indication of the number of
painful moments per treatment group. Since NRS
scores are recorded often per patient, we set the
non-inferiority margin on 20%, assuming that this
would reflect a clinically relevant difference.
Non-inferiority will be assessed by using a one-sided
97.5% confidence interval for the difference in the
percentage of patients with at least one NRS score of
4 or higher between the paracetamol group and the
morphine group, and non-inferiority will be proven if
the upper limit of this confidence interval is lower
than 20%. The confidence interval will be calculated
by using the method of Klingenberg [60] with
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adjustment for center. With data from our previous
study [10] on paracetamol and morphine, it is esti-
mated that 60% of all patients will have one or more
NRS scores of more than 3. Using a simulation study,
we calculated that to detect non-inferiority with a
power of 75%, 200 patients (100 per group) would be
required. Even though the power is 75%, this is con-
sidered to be sufficient for this secondary endpoint.
This means that the sample size of 104 patients per
group is sufficient for the non-inferiority analysis.
Randomization, blinding, and treatment allocation
Blocked randomization with randomly chosen block
size and stratification by center will be used. The
randomization schedule will be kept in the local
pharmacy at every center. To ensure concealed allo-
cation, the pharmacist is the only person to have
access to the randomization schedule. The
randomization schedules are made by the study’s
biostatistician. Study medication will be prepared at
the participating centers. We will use standard mor-
phine and paracetamol formulations.
In case of a medical emergency, the pharmacists can
be consulted regarding what medication was adminis-
tered to a patient.
Statistical methods
The non-parametric Van Elteren test with stratification
by center will be used to compare the primary outcome
of cumulative age-adjusted morphine between groups.
Analysis of secondary outcomes will include length
of PICU stay, number of hours on ventilation, and
concomitant use of sedatives. These secondary out-
comes will be compared by using linear regression
analysis with group and treatment center as categor-
ical independent variables. Analysis using linear re-
gression models will be performed with cumulative
rescue morphine (first 48 h) as outcome variable and
group (morphine versus paracetamol) as predictor
variable. Center, Down syndrome (yes/no), and cyan-
otic versus non-cyanotic cardiac defects will be
added as covariates. Robust regression models will
be used when necessary (i.e., when the outcome vari-
able is non-normally distributed).
In a secondary, non-inferiority analysis, we will
also compare the number of patients with one or
more NRS scores of 4 or higher between the two
groups by using a non-inferiority margin of 20%.
Non-inferiority will be assessed by using a one-sided
97.5% confidence interval for the difference in the
percentage of patients with at least one NRS score
of 4 or higher between the paracetamol group and
the morphine group, and non-inferiority will be
proven if the upper limit of this confidence interval
is lower than 20%. The confidence interval will be
calculated by using the method of Klingenberg [60]
with adjustment for center.
Adverse drug reactions will be specified as
hemodynamic, gastrointestinal, respiratory reactions
or pediatric delirium, as previously described. Ad-
verse effects and other dichotomous outcomes, such
as re-intubation, will be compared between groups
by using Fisher’s exact tests, and the uncertainty in
these estimated proportions will be assessed by using
95% confidence intervals. The level of significance
will be set at 5%, and all tests will be two-sided.
NONMEM will be used to perform population PK
analysis.
Safety
Patients can be withdrawn from the study at any time by
the investigator or the treating physician. The
intention-to-treat analysis will include all subjects. The
subjects that have been withdrawn during the study will
be included only for the time period in which they have
participated. The cumulative morphine requirement will
be calculated for the time that the patient participated in
the study.
An external data safety monitoring board (DSMB) com-
posed of pediatric intensivists and cardio-anesthesiologist
with extensive clinical and research experience in the field
of analgosedation in the PICU is established. The study
protocol does not contain an interim analysis. The sec-
ondary endpoints require more included patients than the
primary endpoint. An interim analysis could terminate the
trial prematurely on the basis of a favorable primary out-
come while not having enough power to assess secondary
endpoints. However, the DSMB can advise us to stop the
trial if necessary. The DSMB has advised the researchers
during the study set-up and evaluated study proceedings
after inclusion of the first 10 patients. The DSMB evalu-
ated inclusion rate and safety of participants (need for res-
cue morphine in both groups) several times during the
inclusion period, and the last meeting was in October
2017. The DSMB advised us to continue the study without
changes to the protocol.
An advisory board composed of representatives from two
patient and parent associations (Stichting Kind en Zieken-
huis and Patientvereniging Aangeboren Hartafwijkingen), a
neonatologist and clinical pharmacologist, and a pediatric
cardiologist is established. The advisory board has
been involved in the design of the study and parental
participation.
Data management and monitoring
Data are collected through case report forms in OpenCli-
nica, a web-based database (OpenClinica, LCC, Waltham,
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MA, USA), supported by the Erasmus MC. Range checks
for data values were added in the Code of Federal Regula-
tions (CRF), if possible, to promote data quality. Data man-
agement is coordinated by the Erasmus MC researchers
and trial support unit. All participants receive a trial ID,
and the personal details are known only to the researchers,
pharmacy, and attending physician. Double data entry and
validation are carried out by all participating centers. Moni-
toring of the data and trial proceedings is coordinated by
the Erasmus MC. Monitoring of the data and trial proceed-
ings is carried out per research site before the start of the
trial, soon after the start of the trial, and three times a year
for the duration of the trial. A close-out visit is carried out
after completion of the inclusion period per research site.
Trial auditing is carried out only by invitation from the
hospital board and its frequency is not specified.
The Erasmus MC, as the coordinating center, owns in-
tellectual property. The investigators have unlimited
access to the final dataset. A newsletter with the study re-
sults will be made available on the website of the patient
and parent organizations and will be sent to participants
upon request. Public access to the data and data sharing is
in line with the guidelines of ZonMw (data management
plan), the main funder of this trial. Data access is re-
stricted to authorized use only, and access will be granted
by the researchers upon reasonable request.
Discussion
PK-based dosing of analgesics in children after cardiac
surgery is lacking. IV paracetamol as the primary analgesic
after cardiac surgery could have an opioid-sparing effect
and therefore fewer opioid-related adverse drug reactions.
This study will also provide the necessary PK and PD pa-
rameters to establish a PKPD-based dosing regimen for
analgesics after cardiac surgery. This will lead to a more
individualized dosing regimen to guide clinicians in pro-
viding the best analgesic therapy for their patients.
The results of this trial will be incorporated in an
international guideline for pain treatment after
cardiac surgery in neonates and children who are 0–-
36 months old. This guideline will be endorsed by
several scientific societies for pediatricians and
anesthesiologists.
Trial status
The study was initiated in March 2016. On March
23, 2018, 124 patients had been enrolled in the study.
Enrolment of all 208 patients is expected to be com-
pleted in the fall of 2018. The Standard Protocol
Items Recommendations for Interventional Trials
(SPIRIT) checklist and figure on the trial proceedings
are added as Additional file 1 and Fig. 1, respectively.
STUDY PERIOD
Enrolment Allocation Post-allocation (days) Close-out
TIMEPOINT -t1 0 t0 t1 t2 t3 t4 t15 tx
ENROLMENT:
Eligibility screen X
Informed consent X
Allocation X
INTERVENTIONS:
Study medication 
& PK sampling
PD endpoint 
assessment
Follow-up x
ASSESSMENTS:
Baseline variables
X X
Morphine 
requirement, PK 
and PD parameters
X X X X X X
Follow-up
X X
Fig. 1 SPIRIT figure Pediatric Analgesia after Cardiac Surgery (PACS) study
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Additional files
Additional file 1: SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents*. (DOC 121 kb)
Additional file 2: Short patient information flyer. (PDF 328 kb)
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Appendix
Table 1 Morphine dosing algorithm (adapted from Wang et al. [40])
Weight of patient, kg Dosis, μg/kg per h Dosis, μg/day Continuous infusion, mL/h solution 100 μg/mL
2.5–2.9 3.9 257.4 0.1
3–3.4 5.3 413.4 0.2
3.5–3.9 7.1 639.0 0.3
4–4.4 9.3 948.6 0.4
4.5–4.9 11.4 1299.6 0.5
5–5.4 13.2 1663.2 0.7
5.5–5.9 14.5 2001.0 0.8
6–6.4 15.4 2310.0 1.0
6.5–6.9 16.0 2592.0 1.1
7–7.4 16.4 2853.6 1.2
7.5–7.9 16.6 3087.6 1.3
8–8.9 16.8 3427.2 1.4
9–9.9 16.9 3853.2 1.6
10–10.9 16.8 4233.6 1.8
11–11.9 16.7 4609.2 1.9
12–12.9 16.6 4980.0 2.1
13–13.9 16.5 5346.0 2.2
14–14.9 16.4 5707.2 2.4
15–15.9 16.0 5952.0 2.5
16–16.9 16.0 6336.0 2.6
17–17.9 16.0 6720.0 2.8
18–18.9 16.0 7104.0 3.0
19–19.9 16.0 7488.0 3.1
20–20.9 16.0 7872.0 3.3
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